Regenerative Medicine (RSEA) is one of five territorial marketing companies that owns the rights to all of the drugs developed by Zhittya Genesis Medicine (Zhittya). RSEA’s marketing territory encompasses over 600 million people. Some nations are wealthy, such as Singapore, and some are very poor, like Myanmar. RSEA believes this territory offers multi-billion-dollar sales potential once our medicines are approved in those nations. We also believe that there is a near-term potential for a large stream of medical tourism into RSEA’s clinics in Southeast Asia from the rest of Asia, including China, India, Japan, Korea, and others.

The territory of RSEA includes the following nations: Indonesia, the Philippines, Brunei, Singapore, Malaysia, Vietnam, Laos, Cambodia, Thailand, Myanmar, and East Timor.

RSEA has an agreement with Zhittya, as do all the marketing companies, in which revenues are shared 50% to the territory the patients originate from and 50% to the territory where the patients are treated. This was put in place to cover the scenario where a coronary heart patient (this was Zhittya’s first medical indication for FGF-1) from Saudi Arabia decides to travel to Singapore to seek Zhittya’s heart medicine to save his or her life. If that occurred, Regenerative Medicine of the Middle East-North Africa would get 50% of the revenues and 50% would go to Regenerative Medicine of Southeast Asia, a fair deal for both companies. 

Zhittya has an operational clinic in the British Virgin Islands, and plans to open clinics in 2024 in the Bahamas, Panama, and Mexico to treat Parkinson’s disease subjects who will travel to these clinics from around the world, including the United States, Latin America, Europe, the Middle East, and Southeast Asia.

If any patients from Southeast Asia travel to one of the operational clinics, currently, one in The British Virgin Islands with more to open, RSEA will share in 50% of the revenue. RSEA is also working with Zhittya to open clinics in Southeast Asia. RSEA expects to see cash flow in the fourth quarter of 2024.